Mcl-1在胆盐（GCDA）诱导的肝癌细胞存活与耐药中的作用及机制研究
|
摘要
目的:
研究肝细胞癌、癌旁及正常肝组织中Mcl-1的表达及其临床意义,探讨RNA干扰下调Mcl-1对肝癌细胞生长与药物敏感性的影响,通过研究GCDA对肝癌细胞存活与耐药的作用和可能途径,阐明抗凋亡蛋白Mcl-1在肝细胞癌发生中的作用,分析GCDA调节Mcl-1产生抗凋亡作用的机制,以利于进一步研究新的策略联合靶向Mcl-1,开发肝细胞癌治疗的新方法,开创肿瘤分子靶向治疗的新途径。
方法:
1.采用免疫组化S-P法检测51例肝细胞癌组织、49例癌旁组织和25例正常肝组织中Mcl-1的表达,并结合临床病理特征进行分析。
2.采用免疫荧光法检测GCDA作用前后细胞内蛋白表达强度与细胞内定位的变化。
3.用阳离子脂质体Lipofectamine~(TM) 2000为载体将Mcl-1 siRNA转染至HepG2细胞中,对细胞内Mcl-1基因表达进行干扰。
4.采用MTT法检测GCDA±抗肿瘤药物或抗肿瘤药物±Mcl-1siRNA处理前后肝癌细胞的相对活性与增殖性。
5.采用流式细胞分析法检测抗肿瘤药、GCDA或Mcl-1 siRNA作用前后细胞周期的变化。
6.GCDA±抗肿瘤药物或抗肿瘤药物±Mcl-1 siRNA处理肝癌细胞,Annexin V-FITC和PI合染细胞,荧光显微镜和电镜观察凋亡形态学改变,流式细胞分析法检测细胞凋亡率的变化。
7.采用免疫沉淀法检测GCDA作用下Mcl-1与促凋亡蛋白间的相互结合。
8.提取各方案的细胞总蛋白,采用BCA法检测蛋白浓度,Western Blotting技术检测细胞内待测蛋白的表达变化,β-Tubulin为内参,蛋白带灰度值采用BandScan软件进行分析。
9.采用Comet Assay在单细胞水平上检测GCDA作用后DNA链损伤的情况。
结果:
1.抗凋亡蛋白Mcl-1在肝细胞癌组织和癌旁组织中均有表达,阳性率分别为68.63%和58.10%,与正常肝组织的8.00%相比,差异具有显著性(p＜0.01)。细胞内定位以胞浆为主,部分出现胞核表达。其表达与临床病理特征如性别、年龄、HBV感染、肿瘤大小、肝硬化及病理分级无相关性(p＞0.05),高分化肝细胞癌有较高的阳性表达率(67.86%)。
2.RNA干扰结果显示Mcl-1 siRNA转染24h、48h、72h后Mcl-1蛋白表达明显减少,与未转染组有明显差异(p＜0.01),尤以48小时表达最弱,其灰度值仅为未转染时的27.70%。Mcl-1下调后HepG2细胞中抗凋亡蛋白Bcl-xl表达相应减少,而促凋亡蛋白Bak、Bim和Bax表达稍有增多。
3.MTT结果显示GCDA在短时间内对肝癌细胞株HepG2细胞有增殖作用,以10～20min最明显(p＜0.05);其浓度在200μM内对细胞有增殖作用,以50～200μM处最明显(p＜0.05)。RNA干扰下调Mcl-1后HepG2细胞在抗肿瘤药物作用下的存活率明显低于单纯药物组的存活率(P＜0.05)。
4.流式细胞仪检测结果显示GCDA与转染载体本身对细胞周期与凋亡无明显影响(p＞0.05),RNA干扰下调Mcl-1后HepG2细胞在药物作用下的凋亡率(33.17%)高于单纯药物组的凋亡率(17.60%)(P＜0.05)。
5.免疫荧光结果显示GCDA能使细胞内Mcl-1和pERK表达明显增强,核内表达逐渐加强。Irinotecan处理后pERK和Mcl-1的表达稍有减弱,尤以核内明显。
6.免疫沉淀结果显示GCDA作用后Bak与Bim结合减少,Bim、Bak与Mcl-1结合增加。
7.Western Blotting结果显示GCDA能使HepG2细胞中抗凋亡蛋白Mcl-1表达明显增加,促凋亡蛋白Bim、Bak和Bax表达减少。蛋白合成抑制剂使Mcl-1表达在2-3小时开始衰减,在GCDA存在情况下,Mcl-1在6小时的表达仍很强。Irinotecan处理后pERK和Mcl-1的表达被抑制,在GCDA存在情况下两者表达明显回升。
8.Comet Assay检测结果显示随着GCDA作用浓度的增加HepG2细胞中DNA链损伤程度加重。Western Blotting显示DNA修复蛋白PARP明显增强。
结论:
1.抗凋亡蛋白Mcl-1在肝细胞癌组织中呈过表达状态,在肿瘤发生过程中呈逐渐增强的趋势,高分化肝细胞癌就有较高的阳性表达率,提示肝细胞癌的发生与Mcl-1的抗凋亡作用有关。
2.RNA干扰能有效降低肝癌细胞中Mcl-1蛋白表达水平,Mcl-1蛋白的特异性下调能增加化疗药物作用后肝癌细胞的凋亡率,增强肝癌细胞的药物敏感性。当Mcl-1蛋白水平下调后,与Mcl-1同源的Bcl-2家族抗凋亡成员的功能受到部分抑制,促凋亡蛋白Bax、Bim和Bak功能增强,诱导细胞凋亡。
3.GCDA能诱导肝细胞癌细胞存活与耐药,其作用可能是通过上调抗凋亡蛋白和下调促凋亡蛋白来实现的。
4.GCDA能使肝细胞癌细胞中Mcl-1蛋白表达增强,并阻止Mcl-1在细胞内的降解,增加Mcl-1蛋白在细胞内的稳定性和抗凋亡作用。其机制是通过激活MAPK/ERK1/2信号通道,使ERK磷酸化并向细胞核内转运,激活靶蛋白Mcl-1产生抗凋亡作用。GCDA还能促进Mcl-1中和促凋亡蛋白Bim、Bak的作用使其失活,并减少Bim和Bak的相互结合,阻止细胞色素C的释放,抑制细胞凋亡。
5.GCDA作用下存在DNA的损伤与修复,为下一步研究打下了基础。
Objective
To study expression and clinical significance of Mcl-1 in hepatocellular carcinoma(HCC) tissues,adjacent liver tissues and normal liver tissues.Identify the effects of Mcl-1 down-regulated by RNA interference on survival and drug sensitivity of HCC cells.Investigate the effects and mechanisms of bile salt(GCDA) on apoptosis and chemotherapeutic drug sensitivity of HCC cells.Then on this basis, clarify the role of Mcl-1 in hepatocellular carcinogenesis and its anti-apoptotic mechanism regulated by GCDA.This foundation will provide a combined target to Mcl-1 with a new strategy and explore new method in HCC therapy and create a new way in molecular targeted therapy of tumors.
Methods
1.Expression of Mcl-1 were detected in 51 HCC tissues,49 adjacent liver tissues and 25 normal liver tissues by Strepavidin-peroxidase immunohistochemistry staining(SP method) and analyzed with clinical pathological characteristics.
2.Changes of protein expression and subcellular localization were detected by immunofluorescence method after GCDA treatment in HCC cells.
3.Human HCC cell line HepG2 was cultured in vitro and transfected with Mcl-1 siRNA by Lipofectamine~(TM) 2000 which interfering the expression of Mcl-1.
4.HepG2 cells were treated with GCDA±chemotherapeutic drug or chemotherapeutic drug±Mcl-1 siRNA.Cell viability and proliferation were detected by MTT assay.
5.Cells were treated with chemotherapeutic drugs,GCDA or Mcl-1 siRNA.Cell cycle was assayed by Flow Cytometry(FCM).
6.HepG2 cells were treated with GCDA±chemotherapeutic drug or chemotherapeutic drug±Mcl-1 siRNA and dyed with Annexin V-FITC and PI.Cell apoptosis morphology was observed by fluorescence microscope or electron microscope.Cell apoptotic rate was assayed by Flow Cytometry(FCM).
7.The interaction of Mcl-1 and pro-apoptotic proteins was assessed by immunoprecipitation(IP) and Western Blotting(WB) after GCDA treatment.
8.Total protein of HCC cells was extracted,and the concentration was measured by BCA method.Expressions of apoptosis-regulating proteins were assessed by Western Blotting.The reference gene wasβ-Tubulin.Gray scale values of proteins were analyzed by BandScan software.
9.DNA strand damage after GCDA treatment was assessed by Comet Assay in single cell level.
Results
1.Mcl-1 was expressed in HCC tissues and adjacent liver tissues with the positive rate of 68.63%and 58.10%,respectively.Compared to 8%of normal liver tissues,they had markedly significance of difference (p＜0.01).Intracellular location of Mcl- 1 was mainly in cytoplasm,partly in nuclei.The expression of Mcl-1 had no relationship with clinical pathological characteristic such as gender,age,HBV infection,tumor size and pathology grade(p＞0.05).However,the positive rate in well-differentiated HCC tissues was high to 67.86%.
2.The results of RNA interference indicated expression of Mcl-1 protein was down-regulated obviously after Mcl-1 siRNA was transfected to HepG2 cells about 24h,48h,72h.The level of Mcl-1 protein had significance of difference(p＜0.01) to control group,especially after 48h, which the gray scale value was 27.70%of control group.After Mcl-1 was down-regulated in HepG2 cells,expression of anti-apoptotic protein such as Bcl-xl decreased while pro-apoptotic proteins such as Bak,Bim,Bax increased slightly.
3.The results of MTT indicated GCDA had proliferation effect to HepG2 cells within short time,especially 10-20rain(p＜0.05),or with concentration lower than 200μM,especially 50～200μM(p＜0.05).With the treatment of chemotherapeutic drugs in HepG2 cells,the survival rate after Mcl-1 siRNA was significantly lower than single drug group(P＜0.05).
4.FCM results indicated GCDA or Lipofectamine~(TM) 2000 had no effect to cell cycle and apoptosis(p＞0.05).With the treatment of chemotherapeutic drugs in HepG2 cells,cell apoptotic rate after Mcl-1 down-regulation(33.17%) was markedly higher than single drug group (17.60%)(P＜0.05).
5.Immunofluorescence results indicated GCDA strengthened cellular expression of Mcl-1 and pERK,especially in nuclei.Expression of Mcl-1 and pERK weakened slightly after treatment of Irinotecan, especially in nuclei.
6.Immunoprecipitation results indicated the binding of Bak/Bim reduced after GCDA treatment while Bak/Mcl-1 and Bim/Mcl-1 bingding increased.
7.Western Blotting results indicated GCDA increased the expression of anti-apoptotic protein Mcl-1 and decreased the expression of pro-apoptotic proteins such as Bim,Bak and Bax.Though protein synthesis inhibitor made Mcl-1 degradation in 2 to 3 hours,the time was last to over 6 hours at the co-presence of GCDA.The expressions of pERK and Mcl-1 were inhibited after treatment of Irinotecan and revived at the co-presence of GCDA.
8.Comet Assay results indicated DNA strand damage of HepG2 cells was enhanced gradually when the concentration of GCDA increased. Western Blotting results indicated DNA repair protein PARP was increased obviously.
Conclusions
1.Anti-apoptotic protein Mcl-1 is over-expression in HCC tissues.It has a progressive tendency in tumorigenesis.It has a high positive rate in well-differentiated HCC tissues.This indicates that anti-apoptosis function of Mcl-1 is related to HCC genesis.
2.RNA interference can reduce expression level of Mcl-1 protein in HCC efficiently.Specific down-regulation of Mcl-1 protein increases apoptotic rate of HCC cells with the treatment of chemotherapeutic drugs and enhances drug sensitivity of HCC cells.When Mcl-1 protein level is down-regulated,the function of its homologous anti-apoptotic members in Bcl-2 family is inhibited partly and the pro-apoptotic proteins such as Bax,Bim,Bak are activated to induce cell apoptosis.
3.GCDA can induce cell survival and chemoresistance of HCC cells through up-regulating expression level of anti-apoptotic proteins and down-regulating expression level of pro-apoptotic proteins.
4.GCDA can increase expression of Mcl-1 protein in HCC cells and prevent its degradation,enhance its stability and apoptotic function in cells.The mechanism is that GCDA activate MAPK/ERK1/2 pathway to increase ERK phosphorylation and translocation to nuclei,which activate the target protein Mcl-1 and enhance its anti-apoptotic function.GCDA can promote the binding of Mcl-1/Bim and Mcl-1/Bak,and induce inactivation of pro-apoptotic proteins.It can also reduce the binding of Bim/Bak and prevent cytochrome release and prohibit cell apoptosis.
5.GCDA can induce occurrence of DNA damage and repair,which is a good foundation of further study.
研究肝细胞癌、癌旁及正常肝组织中Mcl-1的表达及其临床意义,探讨RNA干扰下调Mcl-1对肝癌细胞生长与药物敏感性的影响,通过研究GCDA对肝癌细胞存活与耐药的作用和可能途径,阐明抗凋亡蛋白Mcl-1在肝细胞癌发生中的作用,分析GCDA调节Mcl-1产生抗凋亡作用的机制,以利于进一步研究新的策略联合靶向Mcl-1,开发肝细胞癌治疗的新方法,开创肿瘤分子靶向治疗的新途径。
方法:
1.采用免疫组化S-P法检测51例肝细胞癌组织、49例癌旁组织和25例正常肝组织中Mcl-1的表达,并结合临床病理特征进行分析。
2.采用免疫荧光法检测GCDA作用前后细胞内蛋白表达强度与细胞内定位的变化。
3.用阳离子脂质体Lipofectamine~(TM) 2000为载体将Mcl-1 siRNA转染至HepG2细胞中,对细胞内Mcl-1基因表达进行干扰。
4.采用MTT法检测GCDA±抗肿瘤药物或抗肿瘤药物±Mcl-1siRNA处理前后肝癌细胞的相对活性与增殖性。
5.采用流式细胞分析法检测抗肿瘤药、GCDA或Mcl-1 siRNA作用前后细胞周期的变化。
6.GCDA±抗肿瘤药物或抗肿瘤药物±Mcl-1 siRNA处理肝癌细胞,Annexin V-FITC和PI合染细胞,荧光显微镜和电镜观察凋亡形态学改变,流式细胞分析法检测细胞凋亡率的变化。
7.采用免疫沉淀法检测GCDA作用下Mcl-1与促凋亡蛋白间的相互结合。
8.提取各方案的细胞总蛋白,采用BCA法检测蛋白浓度,Western Blotting技术检测细胞内待测蛋白的表达变化,β-Tubulin为内参,蛋白带灰度值采用BandScan软件进行分析。
9.采用Comet Assay在单细胞水平上检测GCDA作用后DNA链损伤的情况。
结果:
1.抗凋亡蛋白Mcl-1在肝细胞癌组织和癌旁组织中均有表达,阳性率分别为68.63%和58.10%,与正常肝组织的8.00%相比,差异具有显著性(p＜0.01)。细胞内定位以胞浆为主,部分出现胞核表达。其表达与临床病理特征如性别、年龄、HBV感染、肿瘤大小、肝硬化及病理分级无相关性(p＞0.05),高分化肝细胞癌有较高的阳性表达率(67.86%)。
2.RNA干扰结果显示Mcl-1 siRNA转染24h、48h、72h后Mcl-1蛋白表达明显减少,与未转染组有明显差异(p＜0.01),尤以48小时表达最弱,其灰度值仅为未转染时的27.70%。Mcl-1下调后HepG2细胞中抗凋亡蛋白Bcl-xl表达相应减少,而促凋亡蛋白Bak、Bim和Bax表达稍有增多。
3.MTT结果显示GCDA在短时间内对肝癌细胞株HepG2细胞有增殖作用,以10～20min最明显(p＜0.05);其浓度在200μM内对细胞有增殖作用,以50～200μM处最明显(p＜0.05)。RNA干扰下调Mcl-1后HepG2细胞在抗肿瘤药物作用下的存活率明显低于单纯药物组的存活率(P＜0.05)。
4.流式细胞仪检测结果显示GCDA与转染载体本身对细胞周期与凋亡无明显影响(p＞0.05),RNA干扰下调Mcl-1后HepG2细胞在药物作用下的凋亡率(33.17%)高于单纯药物组的凋亡率(17.60%)(P＜0.05)。
5.免疫荧光结果显示GCDA能使细胞内Mcl-1和pERK表达明显增强,核内表达逐渐加强。Irinotecan处理后pERK和Mcl-1的表达稍有减弱,尤以核内明显。
6.免疫沉淀结果显示GCDA作用后Bak与Bim结合减少,Bim、Bak与Mcl-1结合增加。
7.Western Blotting结果显示GCDA能使HepG2细胞中抗凋亡蛋白Mcl-1表达明显增加,促凋亡蛋白Bim、Bak和Bax表达减少。蛋白合成抑制剂使Mcl-1表达在2-3小时开始衰减,在GCDA存在情况下,Mcl-1在6小时的表达仍很强。Irinotecan处理后pERK和Mcl-1的表达被抑制,在GCDA存在情况下两者表达明显回升。
8.Comet Assay检测结果显示随着GCDA作用浓度的增加HepG2细胞中DNA链损伤程度加重。Western Blotting显示DNA修复蛋白PARP明显增强。
结论:
1.抗凋亡蛋白Mcl-1在肝细胞癌组织中呈过表达状态,在肿瘤发生过程中呈逐渐增强的趋势,高分化肝细胞癌就有较高的阳性表达率,提示肝细胞癌的发生与Mcl-1的抗凋亡作用有关。
2.RNA干扰能有效降低肝癌细胞中Mcl-1蛋白表达水平,Mcl-1蛋白的特异性下调能增加化疗药物作用后肝癌细胞的凋亡率,增强肝癌细胞的药物敏感性。当Mcl-1蛋白水平下调后,与Mcl-1同源的Bcl-2家族抗凋亡成员的功能受到部分抑制,促凋亡蛋白Bax、Bim和Bak功能增强,诱导细胞凋亡。
3.GCDA能诱导肝细胞癌细胞存活与耐药,其作用可能是通过上调抗凋亡蛋白和下调促凋亡蛋白来实现的。
4.GCDA能使肝细胞癌细胞中Mcl-1蛋白表达增强,并阻止Mcl-1在细胞内的降解,增加Mcl-1蛋白在细胞内的稳定性和抗凋亡作用。其机制是通过激活MAPK/ERK1/2信号通道,使ERK磷酸化并向细胞核内转运,激活靶蛋白Mcl-1产生抗凋亡作用。GCDA还能促进Mcl-1中和促凋亡蛋白Bim、Bak的作用使其失活,并减少Bim和Bak的相互结合,阻止细胞色素C的释放,抑制细胞凋亡。
5.GCDA作用下存在DNA的损伤与修复,为下一步研究打下了基础。
Objective
To study expression and clinical significance of Mcl-1 in hepatocellular carcinoma(HCC) tissues,adjacent liver tissues and normal liver tissues.Identify the effects of Mcl-1 down-regulated by RNA interference on survival and drug sensitivity of HCC cells.Investigate the effects and mechanisms of bile salt(GCDA) on apoptosis and chemotherapeutic drug sensitivity of HCC cells.Then on this basis, clarify the role of Mcl-1 in hepatocellular carcinogenesis and its anti-apoptotic mechanism regulated by GCDA.This foundation will provide a combined target to Mcl-1 with a new strategy and explore new method in HCC therapy and create a new way in molecular targeted therapy of tumors.
Methods
1.Expression of Mcl-1 were detected in 51 HCC tissues,49 adjacent liver tissues and 25 normal liver tissues by Strepavidin-peroxidase immunohistochemistry staining(SP method) and analyzed with clinical pathological characteristics.
2.Changes of protein expression and subcellular localization were detected by immunofluorescence method after GCDA treatment in HCC cells.
3.Human HCC cell line HepG2 was cultured in vitro and transfected with Mcl-1 siRNA by Lipofectamine~(TM) 2000 which interfering the expression of Mcl-1.
4.HepG2 cells were treated with GCDA±chemotherapeutic drug or chemotherapeutic drug±Mcl-1 siRNA.Cell viability and proliferation were detected by MTT assay.
5.Cells were treated with chemotherapeutic drugs,GCDA or Mcl-1 siRNA.Cell cycle was assayed by Flow Cytometry(FCM).
6.HepG2 cells were treated with GCDA±chemotherapeutic drug or chemotherapeutic drug±Mcl-1 siRNA and dyed with Annexin V-FITC and PI.Cell apoptosis morphology was observed by fluorescence microscope or electron microscope.Cell apoptotic rate was assayed by Flow Cytometry(FCM).
7.The interaction of Mcl-1 and pro-apoptotic proteins was assessed by immunoprecipitation(IP) and Western Blotting(WB) after GCDA treatment.
8.Total protein of HCC cells was extracted,and the concentration was measured by BCA method.Expressions of apoptosis-regulating proteins were assessed by Western Blotting.The reference gene wasβ-Tubulin.Gray scale values of proteins were analyzed by BandScan software.
9.DNA strand damage after GCDA treatment was assessed by Comet Assay in single cell level.
Results
1.Mcl-1 was expressed in HCC tissues and adjacent liver tissues with the positive rate of 68.63%and 58.10%,respectively.Compared to 8%of normal liver tissues,they had markedly significance of difference (p＜0.01).Intracellular location of Mcl- 1 was mainly in cytoplasm,partly in nuclei.The expression of Mcl-1 had no relationship with clinical pathological characteristic such as gender,age,HBV infection,tumor size and pathology grade(p＞0.05).However,the positive rate in well-differentiated HCC tissues was high to 67.86%.
2.The results of RNA interference indicated expression of Mcl-1 protein was down-regulated obviously after Mcl-1 siRNA was transfected to HepG2 cells about 24h,48h,72h.The level of Mcl-1 protein had significance of difference(p＜0.01) to control group,especially after 48h, which the gray scale value was 27.70%of control group.After Mcl-1 was down-regulated in HepG2 cells,expression of anti-apoptotic protein such as Bcl-xl decreased while pro-apoptotic proteins such as Bak,Bim,Bax increased slightly.
3.The results of MTT indicated GCDA had proliferation effect to HepG2 cells within short time,especially 10-20rain(p＜0.05),or with concentration lower than 200μM,especially 50～200μM(p＜0.05).With the treatment of chemotherapeutic drugs in HepG2 cells,the survival rate after Mcl-1 siRNA was significantly lower than single drug group(P＜0.05).
4.FCM results indicated GCDA or Lipofectamine~(TM) 2000 had no effect to cell cycle and apoptosis(p＞0.05).With the treatment of chemotherapeutic drugs in HepG2 cells,cell apoptotic rate after Mcl-1 down-regulation(33.17%) was markedly higher than single drug group (17.60%)(P＜0.05).
5.Immunofluorescence results indicated GCDA strengthened cellular expression of Mcl-1 and pERK,especially in nuclei.Expression of Mcl-1 and pERK weakened slightly after treatment of Irinotecan, especially in nuclei.
6.Immunoprecipitation results indicated the binding of Bak/Bim reduced after GCDA treatment while Bak/Mcl-1 and Bim/Mcl-1 bingding increased.
7.Western Blotting results indicated GCDA increased the expression of anti-apoptotic protein Mcl-1 and decreased the expression of pro-apoptotic proteins such as Bim,Bak and Bax.Though protein synthesis inhibitor made Mcl-1 degradation in 2 to 3 hours,the time was last to over 6 hours at the co-presence of GCDA.The expressions of pERK and Mcl-1 were inhibited after treatment of Irinotecan and revived at the co-presence of GCDA.
8.Comet Assay results indicated DNA strand damage of HepG2 cells was enhanced gradually when the concentration of GCDA increased. Western Blotting results indicated DNA repair protein PARP was increased obviously.
Conclusions
1.Anti-apoptotic protein Mcl-1 is over-expression in HCC tissues.It has a progressive tendency in tumorigenesis.It has a high positive rate in well-differentiated HCC tissues.This indicates that anti-apoptosis function of Mcl-1 is related to HCC genesis.
2.RNA interference can reduce expression level of Mcl-1 protein in HCC efficiently.Specific down-regulation of Mcl-1 protein increases apoptotic rate of HCC cells with the treatment of chemotherapeutic drugs and enhances drug sensitivity of HCC cells.When Mcl-1 protein level is down-regulated,the function of its homologous anti-apoptotic members in Bcl-2 family is inhibited partly and the pro-apoptotic proteins such as Bax,Bim,Bak are activated to induce cell apoptosis.
3.GCDA can induce cell survival and chemoresistance of HCC cells through up-regulating expression level of anti-apoptotic proteins and down-regulating expression level of pro-apoptotic proteins.
4.GCDA can increase expression of Mcl-1 protein in HCC cells and prevent its degradation,enhance its stability and apoptotic function in cells.The mechanism is that GCDA activate MAPK/ERK1/2 pathway to increase ERK phosphorylation and translocation to nuclei,which activate the target protein Mcl-1 and enhance its anti-apoptotic function.GCDA can promote the binding of Mcl-1/Bim and Mcl-1/Bak,and induce inactivation of pro-apoptotic proteins.It can also reduce the binding of Bim/Bak and prevent cytochrome release and prohibit cell apoptosis.
5.GCDA can induce occurrence of DNA damage and repair,which is a good foundation of further study.
引文
[1]金小顺,耿小平,朱立新.肝癌多药耐药的研究进展.肝胆外科杂志.2007,15(3):234-236.
[2]Lin Y,Chen SC.Advances for systemic therapy in hepatocellular carcinoma.ONCOLOGY PROGRESS.2007,5(1):79-84.
[3]Richard J.Y.,Andreas S.The BCL-2 protein family:opposing activities that mediate cell death.Nature reviews/molecular cell biology.2008,9:47-59.
[4]Xin,M.,Deng,X..Nicotine inactivation of Bax's proapoptotic function through phosphorylation.J.Biol.Chem.,2005,280:10781-10789.
[5]Wang Q.,Gao F.,May W.S.,et al.Bcl2 negatively regulates DNA double-strand break repair through a non-homologous end joining pathway.Molecular Cell.2008,29:488-498.
[6]Akgul C,Turner PC,White MR,et al.Functional analysis of the human MCL-1gene.Cell Mol Life Sci.2000,57:684-691.
[7]V Labi,M Erlacher,S Kiessling,et al.BH3-only proteins in cell death initiation,malignant disease and anticancer therapy.Cell Death and Differentiation.2006,13:1325-1338.
[8]G(?)linas C,White E.BH3-only proteins in control:specificity regulates MCL-1and BAK-mediated apoptosis.Genes Dev.2005,19(11):1263-1268.
[9]Miao J,Chen GG,Yun JP,et al.Identification and characterization of BH3domain protein Bim and its isoforms in human hepatocellular carcinomas.Apoptosis.2007,12(9):1691-701.
[10]Tsujimoto Y.Role of bcl-2 family proteins in apoptosis:apoptosomes or mitochondria? Genes Cells.1998,3(11):697-707.
[11]ALUN T,CHRIS P,TERRY H,et al.Bryostatin Induces Protein Kinase C Modulation,Mcl-1 Up-Regulation and Phosphorylation of Bcl-2 Resulting in Cellular Differentiation and Resistance to Drug-induced Apoptosis in B-cell Chronic Lymphocytic Leukemia Cells.Leukemia & Lymphoma.2004,45(5):997-1008.
[12]Stephen K.T.,Xiufen Y,Mark G.A.,et al.Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737.Cancer Res.2007,67(3):1176-1183.
[13]T.TAKEHARA,XL LIU,J.FUJIMOTO,et al.Expression and Role of Bcl-xL in Human Hepatocellular Carcinomas. Hepatology. 2001, 34(1):55-61.
[14] Watanabe, F. Kushihata, K. Honda, et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery. 2004, 135(6): 604 - 612.
[15] D Luo, S.C. Cheng, H. Xie, et al. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem. Cell Biol. 2000, 78: 119-126.
[16] Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503
[17] Lu CD, Altieri DC, Tanigawa N, et al. Expression of a novel anti-apoptosis gene survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998, 58(9): 1808-1812.
[18] C. Mann, C. Neal, G. Garcea, et al. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer. 2007, 43(6): 979 - 992.
[19] Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995, 146:1309-1319.
[20] Fleischer B, Schulze-Bergkamen H, Schuchmann M, et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol. 2006, 28 (1): 25-32
[21] Lanxi S., Domenico C., Sandy L., et al. Mcl-1 Regulates Survival and Sensitivity to Diverse Apoptotic Stimuli in Human Non-Small Cell Lung Cancer Cells. Cancer Biology & Therapy. 2005, 4(3): 267-276.
[22] Sugihara S, Nakashima O, Kojiro M, et al. The morphologic transition in hepatocellular carcinoma: A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer. 1992,70(6): 1488-1492.
[23] Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobil Pancreat Surg. 2001, 8(5):404-409.
[24] Wolfgang S, Doris L, Sabine S, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. Journal of Hepatology. 2006, 44: 151-157.
[25] Okita H, Umezawa A, Fukuma M, et al. Acute myeloid leukemia possessing jumping translocation is related to highly elevated levels of EAT/mcl-1, a Bcl-2 related gene with anti-apoptotic functions. Leuk Res. 2000, 24: 73-77.
[26] Katoh O, Takahashi T, Oguri T, et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res. 1998, 58 (23): 5565 -5569.
[27] Kobayashi S, Werneburg NW, Bronk SF, et al. Interleukin-6 contributes to Mcl-1 upregulationand TRAIL resitance via an akt signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005, 128:2054-2065.
[28] Ulrich M, C(?)line C, Allan S.W., et al. Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1. Molecular Cell. 2006, 21: 749-760.
[29] Leonid AS, Shalini ST, Mitchell FD. The Protein Kinase C8 Catalytic Fragment Targets Mcl-1 for Degradation to Trigger Apoptosis J. Biol. Chem, 2006, 281(40): 29703-29710.
[30] Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood, 2002, 100(1): 194-199.
[31] Wirth T, Kuhnel F, Fleischmann-Mundt B. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against hemotherapy and tumor necrosis factor- related apoptosis- inducing ligand by elimination of Mcl-1. Cancer Res. 2005, 65 (16):7393-7402.
[32] Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005, 307:1101-1104.
[33] Davenport R.J.. Gene Silencing. A Faster Way to Shut Down Genes. Science. 2001,292(5521): 1469-1471.
[34] Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol. 2002, 3:672-683.
[35] Wilda M., Fuchs U., Wossmann W., et al. Killing of Leukemic Cells with a Bcr/Abl Fusion Gene by Rna Interference (Rnai). Oncogene. 2002, 21(37): 5716-5724
[36] J.Miao , G. Chen , S. Chun, et al. Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Letters. 2006,236(1):115-124.
[37]Tetsuo T.,Hiroshi T..Suppression of Bcl-xL deamidation in human hepatocellular carcinomas.Cancer Research.2003,63:3054-3057.
[38]Hannon G.J..Rna Interference.Nature.2002,418(6894):244-251.
[39]Agrawal N.,Dasaradhi P.V.,Mohmmed A.,et al.Rna Interference:Biology,Mechanism,and Applications.Microbiol Mol Biol Rev.2003,67(4):657-685.
[40]Monia BP,Holmlund J,Dorr FA.Antisense approaches for the treatment of cancer.Cancer Invest.2000,18:635-650.
[41]Lih-Hwa H.Gene therapy strategies for hepatocellular carcinoma.Journal of Biomedical Science.2006,13:453-468.
[42]Hui KM.Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma.Curr Opin Mol Yher.2007,9(4):378-84.
[43]李银鹏,朱惠明,侯晓华.靶向mcl-1基因的shRNA真核表达质粒的构建与筛选.世界华人消化杂志.2008,16(26):2940-2945.
[44]Schulze-Bergkamen H,Fleischer B,Schuchmann M,et al.Suppression of Mcl-1via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.BMC Cancer.2006,6:232.
[45]张巍,赵蒲,曹大勇,等.siRNA对HepG2细胞mcl-1表达的影响.第四军医大学学报.2007,28(6):530-533.
[46]Weijing Sun.Update in colorectal,hepatobiliary and pancreatic cancers.Update on Cancer Therapeutics.2007,2(3):141-156.
[47]徐雷鸣,王秀玲.胆汁酸代谢与胆结石的关系.新消化病学杂志,1996;4(5):285-286.
[48]Alpini G,Glaser S,Alvaro D,et al.Bile acid depletion and repletion regulate cholangiocyte growth andsecretion by a phosphatidylinositol 3-kinase-dependent pathway in rats.Gastroenterology.2002,123:1226-1237.
[49]Toledo A,Yamaguchi J,Wang JY,et al.Taurodeoxycholate stimulates intestinal cell proliferation and protects against apoptotic cell death through activation of NF-kappa B.Dig Dis Sci.2004,49:1664-1671.
[50]Yamaguchi J,Toledo A,Bass BL,et al.Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression.Surgery.2004,135:215-221.
[51]Milovic V,Teller IC,Faust D,et al.Effects of deoxycholate on human colon cancer cells:apoptosis or proliferation.Eur J Clin Invest.2002,32:29-34.
[52]Pai R,Tarnawski AS,Tran T.Deoxycholic acid activates betacatenin signaling pathway and increases colon cell cancer growth and invasiveness.Mol Biol Cell.2004,15:2156-2163.
[53]Delzenne N.M.,Taper H.S.,Roberfroid M.B..Changes in bile acid metabolism during rat hepatocarcinogenesis:Causative or unrelated.Life Sci.1994,54:1935-1945
[54]Blair P.C.,Popp J.A.,Bryantvarela B.J.,et al.Promotion of hepatocellular foci in female rats by chenodeoxycholic acid.Carcinogenesis.1991,12:59-63
[55]Zhang R,Gong J,Wang H,et al.Bile salts inhibit growth and induce apoptosis of culture human normal esophageal mucosal epithelial cells.World J Gastroenterol.2005,11(41):6466-6471.
[56]Kshama J,Christie L.G.,Rhonda F.S.,et al.Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line.Am J Physiol Gastrointest Liver Physiol.2006,290:G335-G342.
[57]Deuk K.N.,Im E.,Hyun Y.Y.,et al.Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids.Current Cancer Drug Targets.2006,6(8):681-689.
[58]Philippe P.,Olivier R.,Filomena C.,et al.Bile Acids Modulate the Interferon Signalling Pathway.HEPATOLOGY.1999,29:1840-1847.
[59]Kshama J,Vincent T,Christie L,et al.Bile salt exposure causes phosphatidyl-inositol -3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line.Surgery.2004,136(2):160-168.
[60]Kshama R.J.,Christie L.G.,Fiemu N.,et al.PI3 kinase mediates bile salt induced proliferation in a telomerase-immortalized Barrett's cell line.Journal of the American College of Surgeons.2004,199(3):14
[61]许红,王开贞,王玉奎.临床常用药物[M].第2版.济南:山东科学技术出版社.2004:317
[62]V Boige,J-L Raoul,J-P Pignon,et al.Multicentre phase Ⅱ trial of capecitabine plus oxaliplatin(XELOX) in patients with advanced hepatocellular carcinoma:FFCD 03-03 trial.British Journal of Cancer.2007,97:862-867.
[63]殷咏梅,束永前,黄普文,等.奥沙利铂联合氟尿嘧啶、亚叶酸钙治疗结直肠癌肝转移的疗效观察[J].南京医科大学学报,2003,23(3):275
[64]Yuko T,Toshio K,Naoki M,et al.Irinotecan Activates p53 With Its Active Metabolite, Resulting in Human Hepatocellular Carcinoma Apoptosis. J Pharmacol Sci. 2007, 104: 232-242.
[65] Val(?)rie B, Julien T, Mohamed H, et al. Irinotecan as first-line hemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase Ⅱ study with dose adjustment according to baseline serum bilirubin level. EUROPEAN JOURNAL OF CANCER. 2006,42: 456 -459.
[66] Aaron M.D., Julie A.V., Mark A.G., et al. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004, 23: 5301-5315.
[67] Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19(11):1294-1305.
[68] Leu J.I., P. Dumont, M Hafey, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcll complex. Nat Cell Biol, 2004,6 (5):443-450.
[69] A Cuconati, C Mukherjee, D Perez, et al. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003,17(23): 2922-32.
[70] Han J, Goldstein LA, Gastman BR, et al. Disruption of Mcl-1 • Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem. 2005, 280: 16383- 16392.
[71] Osford SM, Dallman CL, Johnson PW, et al. Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr Med Chem, 2004, 11(8): 1031-1039
[72] Mai N, Richard CM, Anne R, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. PNAS,2007, 10: 1073.
[73] Momeny M, Khorramizadeh MR, Ghaffari SH, et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol. 2008, 591(1-3):13-20.
[74] Hugh K.A., Rosalie C.S.. Protein Phosphatase 2A Regulatory Subunit B56a Associates with c-Myc and Negatively Regulates c-Myc Accumulation. MOLECULAR AND CELLULAR BIOLOGY. 2006, 26(7):2832-2844.
[75] Sujoy B., Ramesh M.R., Leonard R.J.. STAT3-mediated transcription of Bcl-2, Mcl-1 and C-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem. J.. 2005 392: 335-344.
[76] Klaus J.S., Jeremias W., Hauke L., et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. Journal of Hepatology. 2008, 48(1): 83-90.
[77] Sieghart W, Fuereder T, Schmid K, et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007, 83(4):425-32.
[78] Masahiko T., Hidetsugu S., Torayuki O., et al. Overexpression of Bcl-2 protects human hepatoma cells from Fas antibody-mediated apoptosis. Journal of Heparology 1999, 31: 315-322.
[79] Mohamad Y.E., Maria D.B., Nazaret L., et al. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clinical Science. 2001, 100:499-508.
[80] Aaron M.D., Jessica H.S., Ruth W.C.. Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal- regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2 A inhibition. The Journal of Biological Chemistry. 2000, 275(28): 21688-21694.
[81] Bong-Jo K, Seung-Wook R, Byoung-Joon S. JNK- and p38 Kinase-mediated Phosphorylation of Bax Leads to Its Activation and Mitochondrial Translocation and to Apoptosis of Human Hepatoma HepG2 Cells. THE JOURNAL OF BIOLOGICAL CHEMISTRY. 2006, 281( 30): 21256-21265.
[82] Qi XJ, Wildey GM, Howe PH. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem. 2006, 281(2):813-23.
[83] Leonid AS, Shalini ST, and Mitchell FD. The Protein Kinase C5 Catalytic Fragment Targets Mcl-l for Degradation to Trigger Apoptosis J. Biol. Chem, 2006, 281(40): 29703-29710.
[84] Saxena A, Viswanathan S, Moshynska O, et al. Mcl-l and Bcl-2 /Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.Am J Hematol. 2004, 75(1): 22-33.
[85] M. van Delft, A. Wei, K. Mason, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006,10(5):389-399.
[86] Di Maso V, Avellini C, Croce LS, et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007, 13(1-2): 89-96.
[87] H Fung, B Demple. A Vital Role for Apel/Refl Protein in Repairing Spontaneous DNA Damage in Human Cells. Molecular Cell. 2005, 17(3):463 - 470.
[1]Tsujimoto Y.Role of bcl-2 family proteins in apoptosis:apoptosomes or mitochondria? Genes Cells,1998;3(11):697-707
[2]Krajewski S,Bodrug S,Krajewska M,et al.Immunohistochemical analysis of Mcl-1 protein in human tissues.Differential regulation of Mcl-1 and Bcl-2protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo.Am J Pathol.1995;146:1309-1319.
[3]Osford SM,Dallman CL,Johnson PW,et al.Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells.CurrMed Chem,2004,11(8):1031-1039
[4]Saxena A,Viswanathan S,Moshynska O,et al.Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.Am J Hematol,2004,75(1):22-33
[5]Nijhawan D,Fang M,Traer E,et al.Elimination ofMcl-1 is required for the initiation of apoptosis following ultraviolet irradiation.Genes and Development,2003,17(6):1475-1486.
[6]Katoh O,Yakahashi T,Oguri T,et al.Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor.Cancer Res,1998,1;58(23):5565-5569.
[7]Derenne S,Monia B,Dean NM,et al.Antisense strategy shows thatMcl-1rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells[J].Blood,2002,100(1):194-199
[8] Michels JO, Neill JW, Dallman CL, et al. Mcl-1 is required for Akata 6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene, 2004,23(28): 4818-4827 [9] Croxton R, Ma Y, Song L, et al. Direct repression of the Mcl-1 promoter by E2F1. Oncogene, 2002, 21(9): 1359-1369
[10] Okita H, Umezawa A, Fukuma M, et al. Acute myeloid leukemia possessing jumping translocation is related to highly elevated levels of EAT/mcl-1, a Bcl-2 related gene with anti-apoptotic functions. Leuk Res 2000; 24: 73-77
[11] Kuo ML, Chuang SE, Lin MT, et al. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene, 2001,20(6):677-685.
[12] Mai N, Richard C.M, Anne R,et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. PNAS,2007,10, 1073
[13] Leonid AS, Shalini ST, and Mitchell FD. The Protein Kinase C 5 Catalytic Fragment Targets Mcl-1 for Degradation to Trigger Apoptosis J. Biol. Chem, 2006, 281(40): 29703-29710.
[14] Choi EM, Kwak SJ, Kim YM, et al. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med 2005; 37: 199-203
[15] Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 2002, 99(3): 1038-1043
[16] Backus HH, Riel JM, Groeningen CJ, et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol. 2001;12:779-785.
[17] Wei LH, Kuo ML, Chen CA, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene,2001,20(41):5799-5810
[18] Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol 2002;3:672-683.
[19] Peng XJ, Wang CP, Ren YQ, et al. Percutaneous radiofreqency ablation treatment of 96 hepatocellular cancer patients under ultrasound guidanc. China Journal of Modern Medicine. 2003,13(4):39-42. Chinese
[20] ZHANG YD, SUN Y. Construction of eukaryotic expression plasmid carrying HSV-TK gene and its expression in HepG2 cell. China Journal of Modern Medicine. 2003,13(22): 6-21
[21] Huether A, Hopfner M, Sutter AP, et al. Erlotinib induces cell cycle arrestand apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol. 2005, 43 (4) :661
[22] Fleischer B, Schulze-Bergkamen H, Schuchmann M, et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol, 2006, 28 (1): 25
[23] Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology, 2006, 43 (1) : 134
[24] Schuchmann M, Schulze-Bergkamen H, Fleischer B, et al. Histone deacetylase inhibition by valproic acid downregulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-and TRAIL receptor-mediated apoptosis and chemotherapy. Oncology Rep, 2006, 15 (1) :227
[25] Zhang Q, Tang X, Lu QY, et al. Resveratrol inhibits hypoxia-induced accumulation of hypoxia- inducible factor 1 alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther, 2005, 4(10) : 1465
[26] Schulze-Bergkamen H, Fleischer B, Schuchmann M, et al. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer, 2006,6:232 [27] Sieghart W, Wackeck V, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol, 2006, 44 (1) : 151
[28] Schepelmann S, Hallenbeck P, et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res, 2005, 65 (12) : 5003
[29] Wirth T, Kuhnel F, Fleischmann-Mundt B. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against hemotherapy and tumor necrosis factor- related apoptosis- inducing ligand by elimination of Mcl-1. Cancer Res, 2005, 65 (16) : 7393
[30] Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 2006, 66(24): 11851-8
[31] Lin Y, Chen SC. Advances for systemic therapy in hepatocellular carcinoma. ONCOLOGY PROGRESS, 2007, 5(1): 79-84
[1]许红,王开贞,王玉奎.临床常用药物[M].第2版.济南:山东科学技术出版社,2004;317
[2]殷咏梅,束永前,黄普文等.奥沙利铂联合氟尿嘧啶、亚叶酸钙治疗结直肠癌肝转移的疗效观察[J].南京医科大学学报,2003,23(3):275
[3]丁小南,袁建华,俞文强,等.奥沙利铂联合方案介入治疗肝癌的研究[J].中国现代应用药学杂志.2006,23(5):418-420
[4]卢栋,李永华,纪龙,等.塞来昔布对人肝癌细胞株HepG2细胞核转录因子-κB活性及蛋白表达的抑制[J].世界华人消化杂志.2008,16(16):1793-1796
[5]Ling YH,J iang JD,Holland J F,et al.Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines[J].Mol Pharmacol,2002,62(3):529.
[6]Liu L,Cao Y,Chen C,et al.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Res,2006,66(24):11851-11858.
[7]Llovet J,Ricci S,Mazzaferro V,et al.Sorafenib imp roves survival in advanced hepatocellular carcinoma(HCC):Results of a phase Ⅲ randomized p lacebocontrolled trial(SHARP trial)[J].Journal of Clinical Oncology,2007,25(18):LBA1.
[8]Faivre SJ,Raymond E,Douillard J,et al.Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma(HCC)[J].Journal of Clinical Oncology,2007,25(18):3546.
[9]Ramanathan R,Belani C,Singh D,et al.Phase Ⅱ study of lapatinib,a dual inhibitor of epidermal growth factor receptor(EGFR) tyrosine kinase 1 and 2 in patients with advanced biliary tree cancer(BTC) or hepatocellular cancer (HCC).A California Consortium(CCC-P) Trial[J].Journal of Clinical Oncology,2006,24(18):4010.
[10]Schwartz JD,Schwartz M,Lehrer D,et al.Bevacizumab in hepatocellular carcinoma(HCC) in patients without metastasis and without invasion of the portal vein[J].Journal of Clinical Oncology,2005,23(16):4122.
[11]Sun W,Haller DG,Mykulowycz K,et al.Combination of capecitabine,oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma(HCC):A phase Ⅱ study[J].Journal of Clinical Oncology,2007,25(18):4574.
[12]H(?)pfner M,Sutter AP,Huether A,et al.Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma[J].J Hepatol,2004,41(6):1008-1016.
[13]朱步东,袁守军,徐建明,等.易瑞莎对肝癌小鼠的抑癌作用[J].中华医学杂志,2004,84(8):684-686.
[14]Huether A,Hpfner M,Sutter AP,et al.Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics[J].J Hepatol,2005,43(4):661-669.
[15]Zhu AX,Stuart K,Blaszkowsky LS,et al.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma[J].Cancer,2007,110(3):581-589.
[16]邓放,王广义,梁舸,等.组蛋白去乙酰化酶抑制剂与5-FU合用对肝癌细胞HepG2的影响.中国免疫学杂志2008,24:34-37
[17]金小顺,耿小平,朱立新.肝癌多药耐药的研究进展.肝胆外科杂志,2007,15(3):234-236
[18]Scotto KW.Transcriptional regulation of ABC drug transporters[J].Oncogene,2003,22(17):7496-7511.
[2]Lin Y,Chen SC.Advances for systemic therapy in hepatocellular carcinoma.ONCOLOGY PROGRESS.2007,5(1):79-84.
[3]Richard J.Y.,Andreas S.The BCL-2 protein family:opposing activities that mediate cell death.Nature reviews/molecular cell biology.2008,9:47-59.
[4]Xin,M.,Deng,X..Nicotine inactivation of Bax's proapoptotic function through phosphorylation.J.Biol.Chem.,2005,280:10781-10789.
[5]Wang Q.,Gao F.,May W.S.,et al.Bcl2 negatively regulates DNA double-strand break repair through a non-homologous end joining pathway.Molecular Cell.2008,29:488-498.
[6]Akgul C,Turner PC,White MR,et al.Functional analysis of the human MCL-1gene.Cell Mol Life Sci.2000,57:684-691.
[7]V Labi,M Erlacher,S Kiessling,et al.BH3-only proteins in cell death initiation,malignant disease and anticancer therapy.Cell Death and Differentiation.2006,13:1325-1338.
[8]G(?)linas C,White E.BH3-only proteins in control:specificity regulates MCL-1and BAK-mediated apoptosis.Genes Dev.2005,19(11):1263-1268.
[9]Miao J,Chen GG,Yun JP,et al.Identification and characterization of BH3domain protein Bim and its isoforms in human hepatocellular carcinomas.Apoptosis.2007,12(9):1691-701.
[10]Tsujimoto Y.Role of bcl-2 family proteins in apoptosis:apoptosomes or mitochondria? Genes Cells.1998,3(11):697-707.
[11]ALUN T,CHRIS P,TERRY H,et al.Bryostatin Induces Protein Kinase C Modulation,Mcl-1 Up-Regulation and Phosphorylation of Bcl-2 Resulting in Cellular Differentiation and Resistance to Drug-induced Apoptosis in B-cell Chronic Lymphocytic Leukemia Cells.Leukemia & Lymphoma.2004,45(5):997-1008.
[12]Stephen K.T.,Xiufen Y,Mark G.A.,et al.Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737.Cancer Res.2007,67(3):1176-1183.
[13]T.TAKEHARA,XL LIU,J.FUJIMOTO,et al.Expression and Role of Bcl-xL in Human Hepatocellular Carcinomas. Hepatology. 2001, 34(1):55-61.
[14] Watanabe, F. Kushihata, K. Honda, et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery. 2004, 135(6): 604 - 612.
[15] D Luo, S.C. Cheng, H. Xie, et al. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem. Cell Biol. 2000, 78: 119-126.
[16] Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503
[17] Lu CD, Altieri DC, Tanigawa N, et al. Expression of a novel anti-apoptosis gene survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998, 58(9): 1808-1812.
[18] C. Mann, C. Neal, G. Garcea, et al. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer. 2007, 43(6): 979 - 992.
[19] Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995, 146:1309-1319.
[20] Fleischer B, Schulze-Bergkamen H, Schuchmann M, et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol. 2006, 28 (1): 25-32
[21] Lanxi S., Domenico C., Sandy L., et al. Mcl-1 Regulates Survival and Sensitivity to Diverse Apoptotic Stimuli in Human Non-Small Cell Lung Cancer Cells. Cancer Biology & Therapy. 2005, 4(3): 267-276.
[22] Sugihara S, Nakashima O, Kojiro M, et al. The morphologic transition in hepatocellular carcinoma: A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer. 1992,70(6): 1488-1492.
[23] Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobil Pancreat Surg. 2001, 8(5):404-409.
[24] Wolfgang S, Doris L, Sabine S, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. Journal of Hepatology. 2006, 44: 151-157.
[25] Okita H, Umezawa A, Fukuma M, et al. Acute myeloid leukemia possessing jumping translocation is related to highly elevated levels of EAT/mcl-1, a Bcl-2 related gene with anti-apoptotic functions. Leuk Res. 2000, 24: 73-77.
[26] Katoh O, Takahashi T, Oguri T, et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res. 1998, 58 (23): 5565 -5569.
[27] Kobayashi S, Werneburg NW, Bronk SF, et al. Interleukin-6 contributes to Mcl-1 upregulationand TRAIL resitance via an akt signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005, 128:2054-2065.
[28] Ulrich M, C(?)line C, Allan S.W., et al. Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1. Molecular Cell. 2006, 21: 749-760.
[29] Leonid AS, Shalini ST, Mitchell FD. The Protein Kinase C8 Catalytic Fragment Targets Mcl-1 for Degradation to Trigger Apoptosis J. Biol. Chem, 2006, 281(40): 29703-29710.
[30] Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood, 2002, 100(1): 194-199.
[31] Wirth T, Kuhnel F, Fleischmann-Mundt B. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against hemotherapy and tumor necrosis factor- related apoptosis- inducing ligand by elimination of Mcl-1. Cancer Res. 2005, 65 (16):7393-7402.
[32] Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005, 307:1101-1104.
[33] Davenport R.J.. Gene Silencing. A Faster Way to Shut Down Genes. Science. 2001,292(5521): 1469-1471.
[34] Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol. 2002, 3:672-683.
[35] Wilda M., Fuchs U., Wossmann W., et al. Killing of Leukemic Cells with a Bcr/Abl Fusion Gene by Rna Interference (Rnai). Oncogene. 2002, 21(37): 5716-5724
[36] J.Miao , G. Chen , S. Chun, et al. Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Letters. 2006,236(1):115-124.
[37]Tetsuo T.,Hiroshi T..Suppression of Bcl-xL deamidation in human hepatocellular carcinomas.Cancer Research.2003,63:3054-3057.
[38]Hannon G.J..Rna Interference.Nature.2002,418(6894):244-251.
[39]Agrawal N.,Dasaradhi P.V.,Mohmmed A.,et al.Rna Interference:Biology,Mechanism,and Applications.Microbiol Mol Biol Rev.2003,67(4):657-685.
[40]Monia BP,Holmlund J,Dorr FA.Antisense approaches for the treatment of cancer.Cancer Invest.2000,18:635-650.
[41]Lih-Hwa H.Gene therapy strategies for hepatocellular carcinoma.Journal of Biomedical Science.2006,13:453-468.
[42]Hui KM.Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma.Curr Opin Mol Yher.2007,9(4):378-84.
[43]李银鹏,朱惠明,侯晓华.靶向mcl-1基因的shRNA真核表达质粒的构建与筛选.世界华人消化杂志.2008,16(26):2940-2945.
[44]Schulze-Bergkamen H,Fleischer B,Schuchmann M,et al.Suppression of Mcl-1via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.BMC Cancer.2006,6:232.
[45]张巍,赵蒲,曹大勇,等.siRNA对HepG2细胞mcl-1表达的影响.第四军医大学学报.2007,28(6):530-533.
[46]Weijing Sun.Update in colorectal,hepatobiliary and pancreatic cancers.Update on Cancer Therapeutics.2007,2(3):141-156.
[47]徐雷鸣,王秀玲.胆汁酸代谢与胆结石的关系.新消化病学杂志,1996;4(5):285-286.
[48]Alpini G,Glaser S,Alvaro D,et al.Bile acid depletion and repletion regulate cholangiocyte growth andsecretion by a phosphatidylinositol 3-kinase-dependent pathway in rats.Gastroenterology.2002,123:1226-1237.
[49]Toledo A,Yamaguchi J,Wang JY,et al.Taurodeoxycholate stimulates intestinal cell proliferation and protects against apoptotic cell death through activation of NF-kappa B.Dig Dis Sci.2004,49:1664-1671.
[50]Yamaguchi J,Toledo A,Bass BL,et al.Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression.Surgery.2004,135:215-221.
[51]Milovic V,Teller IC,Faust D,et al.Effects of deoxycholate on human colon cancer cells:apoptosis or proliferation.Eur J Clin Invest.2002,32:29-34.
[52]Pai R,Tarnawski AS,Tran T.Deoxycholic acid activates betacatenin signaling pathway and increases colon cell cancer growth and invasiveness.Mol Biol Cell.2004,15:2156-2163.
[53]Delzenne N.M.,Taper H.S.,Roberfroid M.B..Changes in bile acid metabolism during rat hepatocarcinogenesis:Causative or unrelated.Life Sci.1994,54:1935-1945
[54]Blair P.C.,Popp J.A.,Bryantvarela B.J.,et al.Promotion of hepatocellular foci in female rats by chenodeoxycholic acid.Carcinogenesis.1991,12:59-63
[55]Zhang R,Gong J,Wang H,et al.Bile salts inhibit growth and induce apoptosis of culture human normal esophageal mucosal epithelial cells.World J Gastroenterol.2005,11(41):6466-6471.
[56]Kshama J,Christie L.G.,Rhonda F.S.,et al.Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line.Am J Physiol Gastrointest Liver Physiol.2006,290:G335-G342.
[57]Deuk K.N.,Im E.,Hyun Y.Y.,et al.Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids.Current Cancer Drug Targets.2006,6(8):681-689.
[58]Philippe P.,Olivier R.,Filomena C.,et al.Bile Acids Modulate the Interferon Signalling Pathway.HEPATOLOGY.1999,29:1840-1847.
[59]Kshama J,Vincent T,Christie L,et al.Bile salt exposure causes phosphatidyl-inositol -3-kinase-mediated proliferation in a Barrett's adenocarcinoma cell line.Surgery.2004,136(2):160-168.
[60]Kshama R.J.,Christie L.G.,Fiemu N.,et al.PI3 kinase mediates bile salt induced proliferation in a telomerase-immortalized Barrett's cell line.Journal of the American College of Surgeons.2004,199(3):14
[61]许红,王开贞,王玉奎.临床常用药物[M].第2版.济南:山东科学技术出版社.2004:317
[62]V Boige,J-L Raoul,J-P Pignon,et al.Multicentre phase Ⅱ trial of capecitabine plus oxaliplatin(XELOX) in patients with advanced hepatocellular carcinoma:FFCD 03-03 trial.British Journal of Cancer.2007,97:862-867.
[63]殷咏梅,束永前,黄普文,等.奥沙利铂联合氟尿嘧啶、亚叶酸钙治疗结直肠癌肝转移的疗效观察[J].南京医科大学学报,2003,23(3):275
[64]Yuko T,Toshio K,Naoki M,et al.Irinotecan Activates p53 With Its Active Metabolite, Resulting in Human Hepatocellular Carcinoma Apoptosis. J Pharmacol Sci. 2007, 104: 232-242.
[65] Val(?)rie B, Julien T, Mohamed H, et al. Irinotecan as first-line hemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase Ⅱ study with dose adjustment according to baseline serum bilirubin level. EUROPEAN JOURNAL OF CANCER. 2006,42: 456 -459.
[66] Aaron M.D., Julie A.V., Mark A.G., et al. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004, 23: 5301-5315.
[67] Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19(11):1294-1305.
[68] Leu J.I., P. Dumont, M Hafey, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcll complex. Nat Cell Biol, 2004,6 (5):443-450.
[69] A Cuconati, C Mukherjee, D Perez, et al. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003,17(23): 2922-32.
[70] Han J, Goldstein LA, Gastman BR, et al. Disruption of Mcl-1 • Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem. 2005, 280: 16383- 16392.
[71] Osford SM, Dallman CL, Johnson PW, et al. Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr Med Chem, 2004, 11(8): 1031-1039
[72] Mai N, Richard CM, Anne R, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. PNAS,2007, 10: 1073.
[73] Momeny M, Khorramizadeh MR, Ghaffari SH, et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol. 2008, 591(1-3):13-20.
[74] Hugh K.A., Rosalie C.S.. Protein Phosphatase 2A Regulatory Subunit B56a Associates with c-Myc and Negatively Regulates c-Myc Accumulation. MOLECULAR AND CELLULAR BIOLOGY. 2006, 26(7):2832-2844.
[75] Sujoy B., Ramesh M.R., Leonard R.J.. STAT3-mediated transcription of Bcl-2, Mcl-1 and C-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem. J.. 2005 392: 335-344.
[76] Klaus J.S., Jeremias W., Hauke L., et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. Journal of Hepatology. 2008, 48(1): 83-90.
[77] Sieghart W, Fuereder T, Schmid K, et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007, 83(4):425-32.
[78] Masahiko T., Hidetsugu S., Torayuki O., et al. Overexpression of Bcl-2 protects human hepatoma cells from Fas antibody-mediated apoptosis. Journal of Heparology 1999, 31: 315-322.
[79] Mohamad Y.E., Maria D.B., Nazaret L., et al. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clinical Science. 2001, 100:499-508.
[80] Aaron M.D., Jessica H.S., Ruth W.C.. Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal- regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2 A inhibition. The Journal of Biological Chemistry. 2000, 275(28): 21688-21694.
[81] Bong-Jo K, Seung-Wook R, Byoung-Joon S. JNK- and p38 Kinase-mediated Phosphorylation of Bax Leads to Its Activation and Mitochondrial Translocation and to Apoptosis of Human Hepatoma HepG2 Cells. THE JOURNAL OF BIOLOGICAL CHEMISTRY. 2006, 281( 30): 21256-21265.
[82] Qi XJ, Wildey GM, Howe PH. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem. 2006, 281(2):813-23.
[83] Leonid AS, Shalini ST, and Mitchell FD. The Protein Kinase C5 Catalytic Fragment Targets Mcl-l for Degradation to Trigger Apoptosis J. Biol. Chem, 2006, 281(40): 29703-29710.
[84] Saxena A, Viswanathan S, Moshynska O, et al. Mcl-l and Bcl-2 /Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.Am J Hematol. 2004, 75(1): 22-33.
[85] M. van Delft, A. Wei, K. Mason, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006,10(5):389-399.
[86] Di Maso V, Avellini C, Croce LS, et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007, 13(1-2): 89-96.
[87] H Fung, B Demple. A Vital Role for Apel/Refl Protein in Repairing Spontaneous DNA Damage in Human Cells. Molecular Cell. 2005, 17(3):463 - 470.
[1]Tsujimoto Y.Role of bcl-2 family proteins in apoptosis:apoptosomes or mitochondria? Genes Cells,1998;3(11):697-707
[2]Krajewski S,Bodrug S,Krajewska M,et al.Immunohistochemical analysis of Mcl-1 protein in human tissues.Differential regulation of Mcl-1 and Bcl-2protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo.Am J Pathol.1995;146:1309-1319.
[3]Osford SM,Dallman CL,Johnson PW,et al.Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells.CurrMed Chem,2004,11(8):1031-1039
[4]Saxena A,Viswanathan S,Moshynska O,et al.Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.Am J Hematol,2004,75(1):22-33
[5]Nijhawan D,Fang M,Traer E,et al.Elimination ofMcl-1 is required for the initiation of apoptosis following ultraviolet irradiation.Genes and Development,2003,17(6):1475-1486.
[6]Katoh O,Yakahashi T,Oguri T,et al.Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor.Cancer Res,1998,1;58(23):5565-5569.
[7]Derenne S,Monia B,Dean NM,et al.Antisense strategy shows thatMcl-1rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells[J].Blood,2002,100(1):194-199
[8] Michels JO, Neill JW, Dallman CL, et al. Mcl-1 is required for Akata 6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene, 2004,23(28): 4818-4827 [9] Croxton R, Ma Y, Song L, et al. Direct repression of the Mcl-1 promoter by E2F1. Oncogene, 2002, 21(9): 1359-1369
[10] Okita H, Umezawa A, Fukuma M, et al. Acute myeloid leukemia possessing jumping translocation is related to highly elevated levels of EAT/mcl-1, a Bcl-2 related gene with anti-apoptotic functions. Leuk Res 2000; 24: 73-77
[11] Kuo ML, Chuang SE, Lin MT, et al. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene, 2001,20(6):677-685.
[12] Mai N, Richard C.M, Anne R,et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. PNAS,2007,10, 1073
[13] Leonid AS, Shalini ST, and Mitchell FD. The Protein Kinase C 5 Catalytic Fragment Targets Mcl-1 for Degradation to Trigger Apoptosis J. Biol. Chem, 2006, 281(40): 29703-29710.
[14] Choi EM, Kwak SJ, Kim YM, et al. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med 2005; 37: 199-203
[15] Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 2002, 99(3): 1038-1043
[16] Backus HH, Riel JM, Groeningen CJ, et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol. 2001;12:779-785.
[17] Wei LH, Kuo ML, Chen CA, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene,2001,20(41):5799-5810
[18] Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol 2002;3:672-683.
[19] Peng XJ, Wang CP, Ren YQ, et al. Percutaneous radiofreqency ablation treatment of 96 hepatocellular cancer patients under ultrasound guidanc. China Journal of Modern Medicine. 2003,13(4):39-42. Chinese
[20] ZHANG YD, SUN Y. Construction of eukaryotic expression plasmid carrying HSV-TK gene and its expression in HepG2 cell. China Journal of Modern Medicine. 2003,13(22): 6-21
[21] Huether A, Hopfner M, Sutter AP, et al. Erlotinib induces cell cycle arrestand apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol. 2005, 43 (4) :661
[22] Fleischer B, Schulze-Bergkamen H, Schuchmann M, et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol, 2006, 28 (1): 25
[23] Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology, 2006, 43 (1) : 134
[24] Schuchmann M, Schulze-Bergkamen H, Fleischer B, et al. Histone deacetylase inhibition by valproic acid downregulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-and TRAIL receptor-mediated apoptosis and chemotherapy. Oncology Rep, 2006, 15 (1) :227
[25] Zhang Q, Tang X, Lu QY, et al. Resveratrol inhibits hypoxia-induced accumulation of hypoxia- inducible factor 1 alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther, 2005, 4(10) : 1465
[26] Schulze-Bergkamen H, Fleischer B, Schuchmann M, et al. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer, 2006,6:232 [27] Sieghart W, Wackeck V, et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J Hepatol, 2006, 44 (1) : 151
[28] Schepelmann S, Hallenbeck P, et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res, 2005, 65 (12) : 5003
[29] Wirth T, Kuhnel F, Fleischmann-Mundt B. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against hemotherapy and tumor necrosis factor- related apoptosis- inducing ligand by elimination of Mcl-1. Cancer Res, 2005, 65 (16) : 7393
[30] Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 2006, 66(24): 11851-8
[31] Lin Y, Chen SC. Advances for systemic therapy in hepatocellular carcinoma. ONCOLOGY PROGRESS, 2007, 5(1): 79-84
[1]许红,王开贞,王玉奎.临床常用药物[M].第2版.济南:山东科学技术出版社,2004;317
[2]殷咏梅,束永前,黄普文等.奥沙利铂联合氟尿嘧啶、亚叶酸钙治疗结直肠癌肝转移的疗效观察[J].南京医科大学学报,2003,23(3):275
[3]丁小南,袁建华,俞文强,等.奥沙利铂联合方案介入治疗肝癌的研究[J].中国现代应用药学杂志.2006,23(5):418-420
[4]卢栋,李永华,纪龙,等.塞来昔布对人肝癌细胞株HepG2细胞核转录因子-κB活性及蛋白表达的抑制[J].世界华人消化杂志.2008,16(16):1793-1796
[5]Ling YH,J iang JD,Holland J F,et al.Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines[J].Mol Pharmacol,2002,62(3):529.
[6]Liu L,Cao Y,Chen C,et al.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Res,2006,66(24):11851-11858.
[7]Llovet J,Ricci S,Mazzaferro V,et al.Sorafenib imp roves survival in advanced hepatocellular carcinoma(HCC):Results of a phase Ⅲ randomized p lacebocontrolled trial(SHARP trial)[J].Journal of Clinical Oncology,2007,25(18):LBA1.
[8]Faivre SJ,Raymond E,Douillard J,et al.Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma(HCC)[J].Journal of Clinical Oncology,2007,25(18):3546.
[9]Ramanathan R,Belani C,Singh D,et al.Phase Ⅱ study of lapatinib,a dual inhibitor of epidermal growth factor receptor(EGFR) tyrosine kinase 1 and 2 in patients with advanced biliary tree cancer(BTC) or hepatocellular cancer (HCC).A California Consortium(CCC-P) Trial[J].Journal of Clinical Oncology,2006,24(18):4010.
[10]Schwartz JD,Schwartz M,Lehrer D,et al.Bevacizumab in hepatocellular carcinoma(HCC) in patients without metastasis and without invasion of the portal vein[J].Journal of Clinical Oncology,2005,23(16):4122.
[11]Sun W,Haller DG,Mykulowycz K,et al.Combination of capecitabine,oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma(HCC):A phase Ⅱ study[J].Journal of Clinical Oncology,2007,25(18):4574.
[12]H(?)pfner M,Sutter AP,Huether A,et al.Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma[J].J Hepatol,2004,41(6):1008-1016.
[13]朱步东,袁守军,徐建明,等.易瑞莎对肝癌小鼠的抑癌作用[J].中华医学杂志,2004,84(8):684-686.
[14]Huether A,Hpfner M,Sutter AP,et al.Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics[J].J Hepatol,2005,43(4):661-669.
[15]Zhu AX,Stuart K,Blaszkowsky LS,et al.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma[J].Cancer,2007,110(3):581-589.
[16]邓放,王广义,梁舸,等.组蛋白去乙酰化酶抑制剂与5-FU合用对肝癌细胞HepG2的影响.中国免疫学杂志2008,24:34-37
[17]金小顺,耿小平,朱立新.肝癌多药耐药的研究进展.肝胆外科杂志,2007,15(3):234-236
[18]Scotto KW.Transcriptional regulation of ABC drug transporters[J].Oncogene,2003,22(17):7496-7511.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |